Journal
EMBO MOLECULAR MEDICINE
Volume 11, Issue 2, Pages -Publisher
WILEY
DOI: 10.15252/emmm.201809665
Keywords
Alzheimer's disease; astrocytes; astrogliosis; glia; Stat3
Categories
Funding
- European Union (EU) Joint Program, Neurodegenerative Disease Research program, Neurodegenerative Disease Research program (JPND
- Horizon 2020 Framework Programme) [643417/DACAPO-AD]
- Alzheimer Forschung Initiative (AFI)
- German Center for Neurodegenerative Diseases (DZNE)
- Deutsche Forschungsgemeinschaft (DFG) [EXC 1023]
Ask authors/readers for more resources
Reactive astrogliosis is a hallmark of Alzheimer's disease (AD), but its role for disease initiation and progression has remained incompletely understood. We here show that the transcription factor Stat3 (signal transducer and activator of transcription 3), a canonical inducer of astrogliosis, is activated in an AD mouse model and human AD. Therefore, using a conditional knockout approach, we deleted Stat3 specifically in astrocytes in the APP/PS1 model of AD. We found that Stat3-deficient APP/PS1 mice show decreased beta-amyloid levels and plaque burden. Plaque-close microglia displayed a more complex morphology, internalized more beta-amyloid, and upregulated amyloid clearance pathways in Stat3-deficient mice. Moreover, astrocyte-specific Stat3-deficient APP/PS1 mice showed decreased pro-inflammatory cytokine activation and lower dystrophic neurite burden, and were largely protected from cerebral network imbalance. Finally, Stat3 deletion in astrocytes also strongly ameliorated spatial learning and memory decline in APP/PS1 mice. Importantly, these protective effects on network dysfunction and cognition were recapitulated in APP/PS1 mice systemically treated with a preclinical Stat3 inhibitor drug. In summary, our data implicate Stat3-mediated astrogliosis as an important therapeutic target in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available